Latest Media Releases - Noxopharm (Page 8) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Meets with US Advisory Board to Consider Interim NOX66 Radiotherapy Clinical Data (ASX:NOX)

DARRT-1 provides evidence of more abscopal responses Meeting of US Advisory Board in Philadelphia Sydney, 8 August 2018 : Noxopharm (ASX:NOX) today provides a shareholder update on the Company...read more

Release of DARRT-1 Preliminary Safety Data at Clinical Conference (ASX:NOX)

Noxopharm (ASX: NOX) today announces presentation of a poster concerning its DARRT-1 clinical study to the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate Cancer (AN...read more

Noxopharm Announces Pre-Clinical Data Confirms Radio-Enhancing Potential of NOX66 for Paediatric Brain Cancer (DIPG) (ASX:NOX)

Diffuse Intrinsic Pontine Glioma (DIPG); highly aggressive and poorly responsive brain cancer of children Idronoxil (NOX66) significantly enhances ability of radiotherapy to kill DIPG cells. S...read more

Noxopharm, Corporate Presentation June 2018 (ASX:NOX)

Open Briefing June 2018 A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy Unique dual-acting anti-canc...read more

Noxopharm Announces End-of-Study Clinical Data Shows Benefit of NOX66 in Phase 1 Chemotherapy Trial (ASX:NOX)

Data presented at ASCO Annual Meeting CEP-1 Study: NOX66 in combination with low-dose carboplatin in late-stage cancer Ability to halt cancer progress with lower incidence of chemotherapy-ass...read more

Noxopharm, 2018 Mid-Year Investor Briefings (ASX:NOX)

The Company wishes to remind its shareholders and the market generally that a series of mid-year briefings will be held. Noxopharm CEO , Dr Graham Kelly and the Director of Clinical Development and...read more

Noxopharm to Present End-of-Study Clinical Data at ASCO Annual Meeting June 4, 2018 (ASX:NOX)

CEP-1 Study: NOX66 in combination with carboplatin in late-stage cancer Objective: dual benefit of improved anti-cancer effect and lower incidence of chemotherapy-associated side-effects Fina...read more

Noxopharm Announces St Vincent's Hospital Study Passes First Milestone (ASX:NOX)

Combination NOX66 + 177Lutetium-PSMA radionuclide therapy in late-stage prostate cancer Treatment well tolerated in first cohort of 4 patients; second cohort now to start treatment Promising ...read more

Noxopharm DARRT-1 Clinical Study Commences (ASX:NOX)

Multi-national study testing ability of NOX66 to enhance radiotherapy First cohort of patients treated Direct and abscopal responses being evaluated Sydney, 5 April 2018: Noxopharm (ASX:NO...read more

Noxopharm Announces $10.8 Million Raised to Advance its Clinical Program (ASX:NOX)

Noxopharm Limited (ASX:NOX) is pleased to announce the placement of 12,000,000 fully paid ordinary shares to sophisticated and institutional investors at a price of $0.90 per share, to raise $10.8 mil...read more

Noxopharm Announces Evidence of Abscopal Responses in Patients (ASX:NOX)

Presentation at national oncology conference includes first 2 patients treated compassionately with NOX66 + radiotherapy Abscopal responses obtained in both patients Data supports Noxopharm a...read more

Noxopharm, Corporate Presentation: Post-Interim Clinical Data Release (ASX:NOX)

Sydney, 12 March 2018: Noxopharm (ASX:NOX) is pleased to release its latest corporate presentation following the release of an interim report on clinical data from the CEP-1 clinical study. The Com...read more

Noxopharm Reports NOX66 Interim Clinical Trial Data (ASX:NOX)

- NOX66 + low-dose carboplatin in late-stage cancers - Disease progression blocked in the majority of patients (12/14) after 3 months 6 March 2018, Paris: Noxopharm (ASX:NOX) today presented an ...read more

Noxopharm Closes $4M Capital Raising for US Subsidiary, Nyrada, Inc (ASX:NOX)

AUD$4M raised 3 first-in-class drugs identified each drug targeting major community unmet need. Sydney, 16 February 2018: Noxopharm (NOX:ASX) is pleased to announce that it has raised A$4M (be...read more

Noxopharm to use 2016/17 R&D tax rebate for Abscopal Effect research and Brain Cancer project (ASX:NOX)

$855K received for inaugural year of operation Funds to boost key R&D projects in brain cancer and abscopal response Sydney, 17 January 2018: Noxopharm (NOX:ASX) is pleased to announce tha...read more

Viewing: 106 - 120 of 169 Previous | Next